Research & development increased 24.7%
Research & development changed +24.7% from the comparable as-filed period.
$734.0M→$915.0M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +24.7% from the comparable as-filed period.
Gross profit changed +13.1% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.